Diebold Nixdorf vs Xerox
DBD and XRX side by side, both in computer and office equipment. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DBD and XRX compare
Diebold Nixdorf is the larger company, worth 14 times as much as Xerox ($1.9B against $134M).
Xerox grew revenue faster over the last twelve months (16.0% versus 6.3% for Diebold Nixdorf).
Diebold Nixdorf keeps more of each dollar of sales as profit, with a net margin of 2.0% compared with −15.4% at Xerox.
Xerox pays a dividend yielding 9.8%; Diebold Nixdorf does not pay one.
Xerox scores higher on the StockData Score (11 against 8 for Diebold Nixdorf), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DBD | XRX |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $134M |
| Share price | $57.04 | $1.02 |
| Change, 1 year | −12.2% | −66.3% |
| Change, 5 years | – | −94.7% |
| Beta (5Y) | 0.99 | 1.74 |
| Employees | 20K | 23K |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 4 (better) | 3 |
| Growth score | 1 | 2 (better) |
| Performance score | 2 (better) | 0 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 26.7× | – |
| P/S | 0.5× | 0.0× (better) |
| P/B | 2.0× | – |
| EV/EBITDA | 8.0× | – |
| P/FCF | – | 1.8× |
| FCF yield | – | 56.7% |
| Fair value | $91.07 | $46.98 |
| Margin of safety | 37.4% | 97.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 6.3% | 16.0% (better) |
| Revenue growth, 5Y average | −0.50% | 0.00% (better) |
| Net income growth (TTM) | 51.6% | – |
| EPS growth (TTM) | 56.2% | – |
| Profitability | ||
| Gross margin | 25.0% | – |
| Operating margin | 5.4% | – |
| Net margin | 2.0% (better) | −15.4% |
| FCF margin | – | 0.99% |
| Return on equity | 7.5% | – |
| Return on invested capital | 8.1% | – |
| Financial health | ||
| Debt / equity | 1.01 | – |
| Net debt / EBITDA | 2.28 | – |
| Interest coverage | 2.2× | – |
| Current ratio | 1.27 (better) | 1.14 |
| Altman Z-score | 1.84 (better) | 1.17 |
| Piotroski F-score | 8 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 9.8% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | −27.5% |
| Buyback yield | 10.8% | – |
| Shareholder yield | 10.8% (better) | 9.8% |
| Ownership | ||
| Held by institutions | 116% | 98.3% |
| Held by insiders | 58.9% | 39.5% |
| Insider net buying, 12 months | −$126M | – |
| Short interest, % of float | 23.0% | – |
Go deeper
- DBD stock overview
- DBD income statement
- DBD valuation and score
- XRX stock overview
- XRX income statement
- XRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.